B7-H3-targeted CAR-T cells co-expressing 4-1BBL-OX40L fusion protein (Tcelltech)

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameB7-H3-targeted CAR-T cells co-expressing 4-1BBL-OX40L fusion protein (Tcelltech)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionAnti-CD276Tumor necrosis factor receptor superfamily member 4 agonistsTumor necrosis factor receptor superfamily member 9 agonists

TargetsCD276 antigenTumor necrosis factor receptor superfamily member 4Tumor necrosis factor receptor superfamily member 9

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesFuzhou Tcelltech Biological Science and Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesFuzhou Tcelltech Biological Science and Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A